Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ADAMTS4 | O75173 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 3/20 | 0.39 |
| ▸ | MMP14 | P50281 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2155419 | 0.83 | LMNA (0.47) | KDM4EMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL2154986 | 0.83 | LMNA (0.47) | KDM4EMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL2154993 | 0.83 | LMNA (0.47) | KDM4EMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL4956022 | 0.83 | KDM4E (0.48) | KDM4EMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL27713626 | 0.81 | LMNA (0.50) | ALDH1A1NPC1RAB9AADAMTS4CYP3A4 | |
| SCHEMBL2156443 | 0.80 | MAPT (0.45) | KDM4EMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL2155580 | 0.77 | MMP13 (0.55) | KDM4EMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL16493548 | 0.77 | ALDH1A1 (0.46) | MAPTALDH1A1ADAMTS4CYP3A4MEN1 | |
| SCHEMBL2155583 | 0.76 | MAPT (0.45) | KDM4EMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL5507261 | 0.76 | LMNA (0.43) | MAPTALDH1A1ADAMTS4CYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101124213-A | Sulfonylamino cyclic derivatives and uses thereof | SERONO LAB (CH) | 2008-02-13 | — | — | CN | claimed |
| EP-1828160-B1 | SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS | MERCK SERONO SA (CH) | 2011-12-14 | — | — | EP | disclosed |
| US-20080194520-A1 | Sulfonyl Amino Cyclic Derivatives and Use Thereof | MERCK SERONO SA (CH) | 2008-08-14 | — | — | US | disclosed |
| CN-101124213-A | Sulfonylamino cyclic derivatives and uses thereof | SERONO LAB (CH) | 2008-02-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194520-A1 | Sulfonyl Amino Cyclic Derivatives and Use Thereof | GLS2, SRM, GLS | KDM4E 1965/4885MAPT 4423/4885ALDH1A1 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.